Headlines about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.2105818823202 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s analysis:
Several brokerages have weighed in on VIVO. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub cut Meridian Bioscience from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Canaccord Genuity restated a “hold” rating and set a $14.00 price objective on shares of Meridian Bioscience in a research note on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $14.00.
Shares of Meridian Bioscience (VIVO) traded up 3.06% during midday trading on Friday, reaching $15.15. The company had a trading volume of 157,442 shares. The company’s 50-day moving average is $14.48 and its 200-day moving average is $14.44. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $18.58. The stock has a market capitalization of $639.38 million, a PE ratio of 30.30 and a beta of 0.84.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The business had revenue of $50.14 million during the quarter, compared to analysts’ expectations of $49.13 million. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.21 EPS. On average, equities research analysts forecast that Meridian Bioscience will post $0.67 EPS for the current year.
In other Meridian Bioscience news, Chairman John A. Kraeutler purchased 7,000 shares of Meridian Bioscience stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $13.67 per share, with a total value of $95,690.00. Following the acquisition, the chairman now owns 345,230 shares of the company’s stock, valued at approximately $4,719,294.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.30% of the company’s stock.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-meridian-bioscience-vivo-stock-price.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.